Literature DB >> 2298802

The age of osteosarcoma patients is increasing. An epidemiological study of osteosarcoma in Sweden 1971 to 1984.

A Stark1, A Kreicbergs, U Nilsonne, C Silfverswärd.   

Abstract

We conducted an epidemiological study of osteosarcoma in Sweden from 1971 to 1984 to investigate whether the typical features of the disease had changed. Of 294 osteosarcoma patients reviewed, 249 had primary skeletal tumours, and for these the mean annual incidence was 2.1 per million, without any clear trend over time. The mean male/female ratio for the period was 1.6 again with no consistent pattern over time; nor was there any significant change in the distribution of tumours according to location. The only feature which showed a significant change over the 14-year period was the mean age of the patients, being at its lowest (19 years) in 1972 and at its highest (40 years) in 1981. Excluding the 22 patients with craniofacial tumours, the remaining 227 also showed a significant increase in mean age. Analysis of the annual age distribution disclosed an increasing fraction of patients older than those in the classical age peak between 10 and 29 years. A large number of trials have shown improved survival in osteosarcoma over the last 15 years, which has been attributed mainly to adjuvant chemotherapy. The change we have observed in age distribution should also be taken into account in the evaluation of the results of treatment; it may be that older patients have a better prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2298802

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  9 in total

Review 1.  Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment.

Authors:  Rajendra Kumar; Meena Kumar; Kavin Malhotra; Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

2.  Survival analysis of elderly patients with osteosarcoma.

Authors:  Yoshinori Imura; Satoshi Takenaka; Shigeki Kakunaga; Takaaki Nakai; Toru Wakamatsu; Hidetatsu Outani; Takaaki Tanaka; Hironari Tamiya; Kazuya Oshima; Kenichiro Hamada; Norifumi Naka; Nobuhito Araki; Ikuo Kudawara; Takafumi Ueda; Hideki Yoshikawa
Journal:  Int Orthop       Date:  2019-04-22       Impact factor: 3.075

3.  Primary osteosarcoma in patients older than 40 years of age.

Authors:  Dae Geun Jeon; Soo Yong Lee; Wan Hyung Cho; Won Seok Song; Jong Hoon Park
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

4.  Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.

Authors:  Bing Ma; Meng Li; Lei Zhang; Ming Huang; Jun-Bin Lei; Gui-Hong Fu; Chun-Xin Liu; Qi-Wen Lai; Qing-Quan Chen; Yi-Lian Wang
Journal:  Tumour Biol       Date:  2015-10-25

5.  Periosteal pseudotumor in complex total knee arthroplasty resembling a neoplastic process.

Authors:  Madhav Chowdhry; Matthew V Dipane; Edward J McPherson
Journal:  World J Orthop       Date:  2018-05-18

6.  Chemotherapy in primary osteogenic sarcoma in patients over the age of forty.

Authors:  Bulent Ozkurt; Kerem Basarir; Bulent Yalcin; Abdullah Merter; Yusuf Yildiz; Yener Saglik
Journal:  Acta Orthop Traumatol Turc       Date:  2017-02-16       Impact factor: 1.511

7.  The Role of Chemotherapy in the Survival Benefits of Patients Aged Older Than 40 Years With Osteosarcoma.

Authors:  Zhiyou Cao; Yuelin Zhang; Qiang Xu; Xiaolong Yu; Xuqiang Liu; Min Dai
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

8.  Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma.

Authors:  Tao Liu; Xuan-Cheng Fang; Zhen Ding; Ze-Gan Sun; Li-Ming Sun; Yi-Lian Wang
Journal:  FEBS Open Bio       Date:  2015-08-07       Impact factor: 2.693

9.  Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma.

Authors:  Wen-Kai Xia; Zhi-Li Liu; Dong Shen; Qing-Feng Lin; Jun Su; Wei-Dong Mao
Journal:  World J Surg Oncol       Date:  2016-04-29       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.